{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:26:38Z","timestamp":1794489998853,"version":"4.9.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6931,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001]]},"DOI":"10.1093\/annonc\/12.suppl_2.s51","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T01:58:19Z","timestamp":1327024699000},"page":"S51-S61","source":"Crossref","is-referenced-by-count":71,"special_numbering":"S2","title":["Nuclear medicine imaging of neuroendocrine tumours"],"prefix":"10.1016","volume":"12","author":[{"given":"E.","family":"Bombardieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maccauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"de Deckere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Savelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/12.suppl_2.S51_bb0010","first-page":"13","article-title":"Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract","volume":"44","author":"Rindi","year":"2000","journal-title":"Q J Nucl Med"},{"issue":"1","key":"10.1093\/annonc\/12.suppl_2.S51_bb0015","first-page":"3","article-title":"State of the art and future prospects in the management of tumors","volume":"44","author":"\u00d6berg","year":"2000","journal-title":"Q J Nucl Med"},{"issue":"1","key":"10.1093\/annonc\/12.suppl_2.S51_bb0020","first-page":"96","article-title":"New clinical trials for treatment of neuroendocrine tumors","volume":"44","author":"Bajetta","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0025","series-title":"Nuclear Oncology","first-page":"333","article-title":"Receptor Imaging in Oncology","author":"Kurtaran","year":"1999"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0030","series-title":"Nuclear Oncology","first-page":"345","article-title":"Somatostatin Receptor Imaging","author":"Kwekkeboom","year":"1999"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s002590050267","article-title":"Radionuclide imaging of neuroendocrine tumours biological basis and diagnostic results","volume":"25","author":"Seregni","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0001-2998(85)80022-2","article-title":"Radioiodiobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors","volume":"5","author":"McEwan","year":"1985","journal-title":"Semin Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0045","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1021\/jm00317a017","article-title":"Sympathetic nervous system blocking agents III","volume":"10","author":"Short","year":"1967","journal-title":"J Med Chem"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0050","first-page":"1138","article-title":"Iodine-123-4-amino-3-iodobenzylguanidine, a new sympatho-adrenal imaging agent: Comparison with iodine-131-metaiodobenzylguanidine","volume":"27","author":"Shulkin","year":"1986","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0055","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/mpo.2950150406","article-title":"Radiochemistry, biochemistry and kinetics of 131I-MIBG and 123I-MIBG: Clinical implications on the use of 123I-MIBG","volume":"15","author":"Shapiro","year":"1987","journal-title":"Med Pediatr Oncol"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0060","series-title":"Nuclear in Clinical Diagnosis and Treatment","first-page":"745","article-title":"Radiolabelled metaiodobenzylguanidine in the diagnosis of neural crest tumours","author":"Troncone","year":"1994"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0065","first-page":"679","article-title":"Current concepts on the diagnostic use of MIBG in children","volume":"39","author":"Shulkin","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0070","series-title":"Basic and Clinical Aspects of Neurosciences","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-76948-1_1","article-title":"General aspects of the biology and function of somatostatin","author":"Patel","year":"1992"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0075","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.6126003","article-title":"Quantitative electron microscopic autoradiography of insulin, glucagon and somatostatin binding sites on islets","volume":"217","author":"Patel","year":"1982","journal-title":"Science"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0080","first-page":"86","article-title":"Classification and nomenclature of somatostatin receptors","volume":"16","author":"Hoyer","year":"1995","journal-title":"TIPS"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0085","first-page":"5969","article-title":"Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas","volume":"50","author":"Reubi","year":"1990","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0090","series-title":"Basic and Clinical Aspects of Neuroscience","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-76948-1_1","article-title":"General aspects of the biology and function of somatostatin","author":"Patel","year":"1992"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0095","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1210\/jcem-71-3-566","article-title":"Parallel in vitro and in vivo detection of functional somatostatin receptors in human endocrine pancreatic tumours. Consequences regarding the diagnosis and therapy","volume":"71","author":"Lamberts","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0100","first-page":"652","article-title":"Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-tyr-3-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0105","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/0196-9781(94)90146-5","article-title":"Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: Evidence for SSTR2 heterogeneity","volume":"15","author":"Taylor","year":"1994","journal-title":"Peptides"},{"issue":"1","key":"10.1093\/annonc\/12.suppl_2.S51_bb0110","first-page":"50","article-title":"New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy","volume":"44","author":"Virgolini","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0115","first-page":"103","article-title":"Biodistribution of a new chelated somatostatin analogue, [111In-DOTA-Dhe1-Tyr]-octreotide; Comparison with [111in-DTPA-D-Phe1-1]-octreotide in humans","volume":"38","author":"Krenning","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0120","first-page":"1850","article-title":"Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829","volume":"58","author":"Virgolini","year":"1998","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1378\/chest.115.1.224","article-title":"The utility of a somatostatin type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules","volume":"115","author":"Blum","year":"1998","journal-title":"Chest"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0130","first-page":"690","article-title":"Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors","volume":"54","author":"Virgolini","year":"1994","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0135","first-page":"1846","article-title":"In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging","volume":"36","author":"Reubi","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0140","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM199410273311703","article-title":"Vasoactive intestinal peptide (VIP) receptor imaging in the localisation of intestinal adenocarcinomas and endocrine tumors","volume":"331","author":"Virgolini","year":"1994","journal-title":"N Eng J Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0145","first-page":"1732","article-title":"Vasoactivc intestinal peptidereceptor scintigraphy","volume":"36","author":"Virgolini","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0150","series-title":"Diagnostic Nuclear Medicine","first-page":"135","article-title":"Peptide imaging","author":"Virgolini","year":"2000"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0155","first-page":"323","article-title":"A new imaging agent for medullary thyroid cancer","author":"Ohta","year":"1984","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0160","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00006231-199304000-00009","article-title":"Registration of MR and SPECT images in medullary thyroid carcinoma","volume":"14","author":"Chaudhuri","year":"1993","journal-title":"Nucl Med Comm"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0165","first-page":"167","article-title":"Experience in imaging medullary thyroid carcinoma using 99mTc(V) dimercaptosuccinic acid (DMSA)","volume":"37","author":"Clarke","year":"1989","journal-title":"H Ford Hosp Med J"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0170","first-page":"9","article-title":"Anti-CEA antibodies versus octreotide for the detection of metastatic medullary thyroid cancer: Are CEA and somatostatin-receptor expression prognostic factors? In 44th Annual Meeting of the Society of Nuclear Medicine, San Antonio, Texas 1997","volume":"38","author":"Behr","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0175","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/BF01254467","article-title":"In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting","volume":"23","author":"Siccardi","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0180","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0022-3476(84)80122-5","article-title":"Immunolocalization of neuroblastoma using radiolabelled monoclonal antibody UJ13A","volume":"105","author":"Goldman","year":"1984","journal-title":"J Pediatr"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0185","first-page":"2020","article-title":"PET scanning of iodine-124-3F9 as an approach to tumour dosimetry during treatment planning for radioimmunotheraphy in a child with neuroblastoma","volume":"33","author":"Larson","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0190","first-page":"129","article-title":"The role of PET imaging in clinical oncology. A current status report","author":"Shields","year":"1995","journal-title":"Nucl Med Annual"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0195","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/PL00008465","article-title":"Positron emission tomography with 18F-FDG","volume":"126","author":"Pauwels","year":"2000","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/12.suppl_2.S51_bb0200","first-page":"68","article-title":"Use of PET in neuroendocrine tumors. In vivo applications and in vitro","volume":"44","author":"Eriksson","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002590050197","article-title":"Limited value of fluorine-18 fluorodeoxyglucose PET for the imaging of neoroendocrine tumours","volume":"25","author":"Adams","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0210","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.1998.16.7.2534","article-title":"Positron emission tomography (PET) with 5-hydroxytryptophan (5-HTP) in the diagnosis and treatment follow-up of carcinoid tumors","volume":"7","author":"\u00d6rlefors","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0215","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1148\/radiology.195.2.7724749","article-title":"Pancreatic neuroendocrine tumors: Diagnosis with PET","volume":"195","author":"Ahlstr\u00f6m","year":"1995","journal-title":"Radiology"},{"issue":"Suppl","key":"10.1093\/annonc\/12.suppl_2.S51_bb0220","first-page":"28","article-title":"Receptor scintigraphy with 111Inpentetreotide for endocrine gastroenteropancreatic tumors","volume":"27","author":"Joseph","year":"1993","journal-title":"Horm Metab Res"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0225","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0230","first-page":"362","article-title":"Somatostatin receptor scintigraphy in neuroendocrine gastro-entero-pancreatic tumors","volume":"94","author":"Chiti","year":"1997","journal-title":"Radiol Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0235","first-page":"1452","article-title":"SPECT improves accuracy of somatostatin receptors scintigraphy in abdominal carcinoids tumours","volume":"37","author":"Schillaci","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0240","series-title":"Frontiers of Gastro-Intestinal Research, Vol 23. Endocrine Tumors of the Pancreas","first-page":"298","article-title":"Use of radiolabeled somatostatin to localize islet cell tumors","author":"Kwekkeboom","year":"1995"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0245","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1210\/jcem-71-3-566","article-title":"Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors. Consequences with regard to diagnosis, localisation and therapy","volume":"71","author":"Lamberts","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0250","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s002590050314","article-title":"Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours","volume":"25","author":"Chiti","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0255","first-page":"42","article-title":"Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours","volume":"44","author":"Chiti","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0260","first-page":"886","article-title":"Cost-effectiveness analysis of somatostatin receptor scintigraphy","volume":"37","author":"Kwekkeboom","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0265","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0969-8051(96)00066-2","article-title":"123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract","volume":"23","author":"Virgolini","year":"1996","journal-title":"Nucl Med Biol"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2265.1984.tb00054.x","article-title":"Scintigraphy localization of phaeochromocytomas","volume":"20","author":"Fischer","year":"1948","journal-title":"Clin Endocrinol"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0275","first-page":"586","article-title":"131-metaiodobenzylguanidine in localization and treatment of pheochromocytoma","volume":"6","author":"Jakubowski","year":"1985","journal-title":"Nucl Med Commun"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0280","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00842788","article-title":"The diagnostic and therapeutic utility of radioionated metaiodobenzylgnanidine (MIBG): Five years of experience","volume":"16","author":"Troncone","year":"1990","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0285","first-page":"328","article-title":"Localization of pheochromocytoma: MIBG, CT, and MRI correlation","volume":"30","author":"Welchik","year":"1989","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0290","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00006231-198907000-00003","article-title":"Iodine-131-metaiodobenzylguanidine (131-I-MIBG) for the location of suspected pheochromocytoma","volume":"10","author":"Warren","year":"1989","journal-title":"Nucl Med Commun"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0295","first-page":"173","article-title":"Iodine-131- metaiodobenzylguanidine scintigraphy in preoperative an postoperative evaluation of paragangliomas: Comparison with CTand MRI","volume":"34","author":"Maurea","year":"1993","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0300","first-page":"1","article-title":"Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant phaeochromocytoma","volume":"36","author":"Tanenbaum","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0305","first-page":"235","article-title":"Mataiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours","volume":"25","author":"Hoefhagel","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0310","first-page":"308","article-title":"Radionuclide diagnosis and therapy of neural crest tumors using Iodine-131 metaiodobenzylguanidine","volume":"28","author":"Hoefnagel","year":"1987","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0315","series-title":"Nuclear Medicine in Clinical Diagnosis and Teatment","first-page":"1001","article-title":"Childhood neoplasia","author":"Hoefnagel","year":"1998"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0320","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1210\/jcem-61-4-769","article-title":"Comparison of iodobenzylguanidine imaging with computed tomography in locating pheochromocytoma","volume":"61","author":"Chatal","year":"1985","journal-title":"J Clin Endocnnol Metab"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0325","first-page":"576","article-title":"Iodine-131-metaiodobenzylguanidine for the locating of suspected pheochromocytoma: Experience in 400 case","volume":"26","author":"Shapiro","year":"1985","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0330","series-title":"Nuclear Oncology","first-page":"345","article-title":"Somatostatin receptor imaging in oncology","author":"Kwekkeboom","year":"1999"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0335","first-page":"912","article-title":"Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma","volume":"37","author":"Baudin","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0340","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/BF01367593","article-title":"Comparison of 99mTc(V)DMSA, 201T1 and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid","volume":"23","author":"Ugur","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0345","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/0969-8051(96)00031-5","article-title":"Combined use of 111In-DTPA-D-Phel-octreotide (OCT) and 1231-vasoactive intestinal peptide (VIP) in the localization and diagnosis of medullary thyroid carcinoma","volume":"23","author":"Kurtaran","year":"1996","journal-title":"Nucl Med Biol"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0350","first-page":"1","article-title":"Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors","volume":"34","author":"Eising","year":"1995","journal-title":"Nuklearmedizin"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0355","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2436::AID-CNCR16>3.0.CO;2-D","article-title":"Anticarcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: Are carcinoembryonic antigen and somatostatin receptor expression prognosis factors?","volume":"80","author":"Behr","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0360","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00006231-199603000-00003","article-title":"Somatostatin receptor scintigraphy in the staging of small-cell lung cancer","volume":"17","author":"Bohuslavizki","year":"1996","journal-title":"Nucl Med Commun"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0365","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/BF02426696","article-title":"Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma","volume":"21","author":"Kirsch","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0370","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0959-8049(94)00467-J","article-title":"Somatostatin receptor imaging of small-cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy","volume":"31A","author":"Bombardieri","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0375","first-page":"1845","article-title":"The role of iodine-123-Try-3-octreotide scintigraphy in the staging of small-cell lung cancer","volume":"32","author":"Leitha","year":"1991","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0380","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/bjc.1994.144","article-title":"Scintigraphic imaging of small-cell lung cancer with (indium-111)pentetreotide, a radiolabelled somatostatin analogue","volume":"69","author":"O\u2019Byrne","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0385","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/00006231-199311000-00005","article-title":"Somatostatin receptor imaging in small-cell lung cancer using indium-111-DTPA-octreotide: A preliminary study","volume":"14","author":"Maini","year":"1993","journal-title":"Nucl Med Commun"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0390","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/BF00181066","article-title":"The value of octreotide scintigraphy in patients with lung cancer","volume":"21","author":"Kwekkeboom","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0395","first-page":"1397","article-title":"The role of iodine-123-Try-3-octreotide scintigraphy in the staging of small-cell lung cancer","volume":"34","author":"Leitha","year":"1993","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0400","series-title":"Neuroblastoma","first-page":"303","article-title":"Imaging of neuroblastoma and metastasisi","author":"Staalman","year":"2000"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0405","series-title":"Cancer in Children: Clinical Management","first-page":"226","article-title":"Tumours of the sympathetic nervous system, neuroblastoma, ganglioneuroma, phaeochromocytoma","author":"Vo\u00fbte","year":"1992"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0410","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<805::AID-CNCR29>3.0.CO;2-3","article-title":"Metastatic neuroblastoma in children older than one year. Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system","volume":"77","author":"Suc","year":"1996","journal-title":"Cancer"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0415","first-page":"1429","article-title":"Iodine-131-MIBG imaging to monitor chemotherapy response in advanced neuroblastoma: Comparison with laboratory analysis","volume":"35","author":"Maurea","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0420","series-title":"Nuclear Medicine in Clinical Diagnosis and Treatment","first-page":"1067","article-title":"MIBG therapy","author":"Hoefnagel","year":"1998"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0425","doi-asserted-by":"crossref","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH. Somatostatin receptor scintigraphy with (111In-DTPA-D-Phel)-and (123I-Try-3-)octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716\u201331.","DOI":"10.1007\/BF00181765"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0430","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/ajcp\/102.6.752","article-title":"Expression of somatostatin receptor in childhood neuroblastoma","volume":"102","author":"Moertel","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0435","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1210\/jcem-68-4-844","article-title":"The growth hormone responses to octreotide is acromegaly correlate with adenoma somatostatin receptor status","volume":"68","author":"Reubi","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0440","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/BF00285587","article-title":"Somatostin receptor imaging in non-functioning pituitary adenomas: Value of an uptake index","volume":"21","author":"Duet","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0445","first-page":"1449","article-title":"Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands","volume":"37","author":"van Royen","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0450","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bjc.1996.134","article-title":"Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phel-octreotide","volume":"73","author":"W\u00e4ngberg","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0455","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2490::AID-CNCR21>3.0.CO;2-6","article-title":"Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostin receptor scintigraphy","volume":"80","author":"\u00d6hrvall","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0460","first-page":"745","article-title":"Intraoperative lacalization of neuroendocrine tumors with 125-I-TRY(3)-octreotide and a hand-held gamma detecting probe","volume":"114","author":"Schirmer","year":"1993","journal-title":"Surgery"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0465","first-page":"1155","article-title":"Intraoperativa gamma probe detection of neuroendocrine tumors","volume":"39","author":"Adams","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0470","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF00947974","article-title":"Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe","volume":"21","author":"Waddington","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0475","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0039-6060(98)70228-4","article-title":"Intraoperative localization of neuroblastoma in children with 123-I or 125- I radiolabeled metaiodobenzylguanidine","volume":"123","author":"Martelli","year":"1998","journal-title":"Surgery"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0480","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/(SICI)1096-911X(199703)28:3<171::AID-MPO2>3.0.CO;2-G","article-title":"Intraoperative search for neuroblastoma by MIBG and radioguided surgery with the gamma detector","volume":"28","author":"Heij","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0485","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0001-2998(97)80042-6","article-title":"PET in oncology: Will it replace the other modalities?","volume":"27","author":"Hoh","year":"1997","journal-title":"Semin Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0490","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s002689900439","article-title":"Neuroendocrine tumor imaging: Can FDG PET detect tumors with poor prognosis and agressive behaviour?","volume":"22","author":"Pasquali","year":"1998","journal-title":"World J Surg"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0495","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/BF00801625","article-title":"FDG PET imaging of paragangliomas of the neck comparison with MIBG SPECT","volume":"22","author":"McFerlane","year":"1995","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0500","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0039-6060(97)90208-7","article-title":"Evaluation of FDG PET and its association with glucose transporter expression in medullary thyroid carcinoma and feocromocitoma","volume":"122","author":"Musholt","year":"1997","journal-title":"Surgery"},{"key":"10.1093\/annonc\/12.suppl_2.S51_bb0505","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/BF03348014","article-title":"Potential role of FDG PET in the staging of primitive and recurrent MTC","volume":"20","author":"Gasparoni","year":"1997","journal-title":"J Endocrinol Invest"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419544969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419544969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/suppl_2\/S51\/787440\/12-suppl_2-S51.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T12:00:23Z","timestamp":1589457623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419544969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":100,"alternative-id":["S0923753419544969"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/12.suppl_2.s51","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001]]}}}